THE ROLE OF APOPTOSIS VIOLATIONS IN THE JUVENILE IDIOPATHIC ARTHRITIS FORMATION
https://doi.org/10.15690/pf.v9i3.322
Abstract
We investigated the polymorphism of the gene p53 exon 4 Arg72Pro and intron 3 ins/del 16 b. p. in children with juvenile idiopathic arthritis in order to identify the influence of gene polymorphisms on the course and outcome of the disease. The children were divided into several groups according to the sex, type of articular lesion and the effectiveness of treatment. The main criteria of therapy effectiveness was defined as achieving "inactive" arthritis as well as a clinical (pharmacologic) remission. The correlation between p53 gene genotypes among girls with oligo-, polyarthritis of juvenile idiopathic arthritis was shown for the first time. The data obtained demonstrates the necessity for further studies of the correlation between genotype p53 and juvenile idiopathic arthritis.
About the Authors
A. N. Kozhevnikov
Saint-Petersburg Pediatric Medical Academy, Russian Federation
Saint-Petersburg Research Pediatric Orthopedic Institute n. a. G.I. Turner, Russian Federation
Russian Federation
Russian Federation
M. V. Moskalenko
Saint-Petersburg State University, Department of Genetics & Breeding, Russian Federation
Russian Federation
Russian Federation
N. A. Pozdeeva
Saint-Petersburg Research Pediatric Orthopedic Institute n. a. G.I. Turner, Russian Federation
Russian Federation
Russian Federation
G. A. Novik
Saint-Petersburg Pediatric Medical Academy, Russian Federation
Russian Federation
Russian Federation
V. I. Larionova
Saint-Petersburg Pediatric Medical Academy, Russian Federation
Russian Federation
Russian Federation
References
1. Алексеева Е. И., Литвицкий П. Ф. Ювенильный ревматоидный артрит: этиология, патогенез, клиника, алгоритмы диагностики и лечения. Руководство для врачей, преподавателей, научных сотрудников / под общ. ред. А. А. Баранова. М.: Веди. 2007. 360 с.
2. Gay S., Gay R. E., Koopman W. J. Molecular and cellular mechanisms of joint destruction in rheumatoid arthritis: two cellular mechanisms explain joint destruction? Annals of the Rheumatic Diseases. 1993; 52: 39–44.
3. Muller-Ladner U., Ospelt C., Gay S. et al. Cells of the synovium in rheumatoid arthritis. Synovial fibroblasts. Arthritis Research Therapy. 2007; 9: 223.
4. Huber L. C., Distler O., Tarner I. et al. Synovial fibroblasts: key players in rheumatoid arthritis. Rheumatology. 2006; 45: 669–675.
5. Vogelstein B., Kinzler K. W. Р53 function and dysfunction. Cell. 1992; 70: 523–526.
6. Hollstein M., Sidransky D., Vogelstein B. et al. Р53 mutations in human cancers. Science. 1991; 253 (5015): 49–53.
7. Dumont P., Leu J., Della A. C. et al. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nature Genetics. 2003; 33: 357–365.
8. Arends M. J., Morris R. G., Wyllie A. H. Apoptosis. The role of the endonuclease. Am J Pathology. 1990; 136 (3): 593–608.
9. Choisy-Rossi C., Reisdorf P., Yonish-Rouach E. The p53 tumor suppressor gene: structure, function and mechanism of action. Results and problems in cell differentiation. 1999; 23 (1): 45–72.
10. Inhibition of the p53-MDM2 interaction: targeting a proteinprotein interface. Patrick Che`ne. Molecular Cancer Research. 2004; 2: 20–28.
11. Laptenko O., Prives C. Transcriptional regulation by p53: one protein, many possibilities. Cell Death Differention. 2006; 13: 951–961.
12. Sakamuro D., Sabbatini P., White E. et al. The polyproline region of p53 is required to activate apoptosis but not growth arrest. Oncogene. 1997; 15: 887–898.
13. Kristen K., Walker A., Arnold J. Levine Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc. Natl. Acad. Sci. 1996; 93: 15335–15340.
14. Ara S., Lee P. S. Y., Hansen M. F. et al. Codon 72 polymorphism of the TP53 gene. Nucleic Acids Research. 1990; 18 (16): 4961.
15. Dumont P., Leu J. et al. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nature Genetics. 2003; 33: 357–365.
16. Sallivan A., Syed N., Gasco M. et al. Polymorphism in wildtype p53 modulates response to chemotherapy in vitro and in vivo. Oncogene. 2004; 23: 3328–3337.
17. Yamanishi Y., Boyle D. L., Pinkoski M. J. et al. Regulation of joint destruction and inflammation by p53 in collagen-Induced arthritis. American Journal of Pathology. 2002; 160: 123–130.
18. Wu X., Zhao H., Amos C. I. et al. p53 genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J. Natl. Cancer Inst. 2002; 94 (9): 681–690.
19. Macchioni P., Nicoli D., Casali B. et al. The codon 72 polymorphic variants of p53 in Italian rheumatoid arthritis patients. Clin Exp Rheumatol. 2007; 25 (3): 416–421.
20. Lee Y. H., Kim Y. R., Ji J. D. et al. P53 codon 72 polymorphism and rheumatoid arthritis. J. Rheumatol. 2001; 28 (11): 2392–2394.
21. Moodley D., Mody G. M., Chuturgoon A. A. et al. Functional analysis of the p53 codon 72 polymorphism in black South Africans with rheumatoid arthritis — a pilot study. Clin Rheumatol. 2010; 29: 1099–1105.
22. Taubert H., Thamm B., Meye A. et al. The p53 status in juvenile chronic arthritis and rheumatoid arthritis. Clin Exp Immunol. 2000; 122: 264–269.
23. Хайрутдинов В. Р., Суспицын Е. Н., Буслов К. Г. и др. Особенности распределения аллелей 72 кодона гена р53 у больных псориазом. Материалы юбилейной научной конференции молодых ученых Северо-Западного региона. Медицинский академический журнал. 2004; 4 (3): 72–73.
24. Чердынцева Н. В., Слонимская Е. М., Белявская В. А. и др. Исследование связи полиморфизма генов онкосупрессора p53, гена хемокинового рецептора CCR5 и их сочетаний с риском развития и прогрессированием рака молочной железы. Молекулярная медицина. 2007; 1: 23–31.
25. Петросян Э. К., Ильенко Л. И., Цыгин А. Н. и др. Влияние полиморфизма гена р53 на течение и исходы хронического гломерулонефрита у детей и подростков. Педиатрия. 2006; 5: 4–7.
26. Спицина Е. В., Якунина Н. Ю., Чудакова Д. А. и др. Ассоциация полиморфизма маркеров Pro72Arg и C (-594)CC гена р53 с диабетической полинейропатией при сахарном диабете типа I в русской популяции г. Москвы. Молекулярная биология. 2007; 41 (6): 989–993.
27. Гервас П. Ф., Литвяков Н. В., Стахеева Н. М. и др. Влияние поли морфизма генов апоптоза и репарации на эффективность неоадъювантной химиотерапии злокачественных новообразований. Сибирский онкологический журнал. 2009; 4: 41–47.
28. Казначеев К. С., Белявская В. А., Ляхович В. В. и др. Варианты полиморфных изменений генов р53, XRCC1 и XPD у детей с острым лимфобластным лейкозом. Бюллетень сибирской медицины. 2008; 2: 47–53.
29. Поспелова Т. И., Воевода М. И., Воропаева Е. Н. и др. Значение конституциональных полиморфизмов гена р53 у больных неходжкинскими злокачественными лимфомами. Бюллетень сибир ской медицины. 2008; 3: 56–63.
30. Lovell D. J., Giannini E. H., Reiff A. et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med. 2000; 342: 763–769.
31. Wallace C. A., Ruperto N., Giannini E. et al. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol. 2004; 31: 2290–2294.
32. Wallace C. A. Current management of juvenile idiopathic arthritis. Practice Research Clinical Rheumatology. 2006; 20 (2): 279–300.
33. Albornoz M. A. ACR formally adopts improvement criteria for juvenile arthritis (ACR pediatric 30). ACR News. 2002; 21: 3.
Review
For citations:
Kozhevnikov A.N., Moskalenko M.V., Pozdeeva N.A., Novik G.A., Larionova V.I. THE ROLE OF APOPTOSIS VIOLATIONS IN THE JUVENILE IDIOPATHIC ARTHRITIS FORMATION. Pediatric pharmacology. 2012;9(3):52-57. (In Russ.) https://doi.org/10.15690/pf.v9i3.322
Views:
650
Email this article 